Details

NameSymbolSector
ANG LIFESCIENCES INDIA LIMITEDANGPharmaceuticals
Open
36.5
High
36.5
Low
35
Close
35.31
Volume
1895
Exchange
bse
Time
03-Oct-2025

Outlook

Score:  

2

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Ang Lifesciences India is  
Opening Marubozu
Estimated Stoploss of Ang Lifesciences India is ₹  
36.5
Ang Lifesciences India has a  
Bearishℹ
 pattern. 
Formation of  
Opening Marubozu
 candle pattern indicates Ang Lifesciences India has chances of  
Continuationℹ
 of the current trend. 

Trend

Ang Lifesciences India is in  
Sideways trendℹ
. 
Price of Ang Lifesciences India is  
Upℹ
 by  

11.67

%. 
Target
Buy @ 

24.86

Sell @ 

37.04

Current @ 

35.31

Volume

The trade volumes of Ang Lifesciences India have become  
Deficientℹ
Though the volume trend for Ang Lifesciences India appears  
Bullishℹ
 the participants seem to be  
Weak Buyersℹ
The trade volume of Ang Lifesciences India is  

Down

 by  

77.71

% 

Valuation

The current market price of Ang Lifesciences India is  
Undervaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 208cr and total assets worth ₹ 208cr, the balance sheet of Ang Lifesciences India is:  
Balancedℹ
. 
Cashflow
Ang Lifesciences India has  
Insufficientℹ
 cash flow because it is  

₹ 0cr

. It is  
Downℹ
 by  

0

%. 

(*Mar 2025)

0% i.e. ₹ 2cr spent in operatingℹ
50% i.e. ₹ 1cr spent in investingℹ
50% i.e. ₹ 3cr earned in financingℹ
0% in otherℹ
Income
The income of Ang Lifesciences India is  

₹ 24cr

 and  

Loss

 is :  

₹ 0cr

(*Jun 2025)

Ang Lifesciences India Losses decreased by:  

60

% and Income is Down by:  

29.17

% 

(*Jun 2025)

The income of Ang Lifesciences India is  

₹ 18cr

 and  

Loss

 is :  

₹ 1cr

(*Mar 2025)

Ang Lifesciences India Losses increased by:  

150

% and Income is Down by:  

27.27

% 

(*Mar 2025)

The income of Ang Lifesciences India is  

₹ 23cr

 and  

Loss

 is :  

₹ 4cr

(*Dec 2024)

Ang Lifesciences India Losses decreased by:  

33.33

% and Income is Up by:  

73.68

% 

(*Dec 2024)

By using this site you agree to the use of cookies to deliver a better site experience.